期刊文献+

巨噬细胞免疫代谢与动脉粥样硬化的研究进展 被引量:25

Advances in studies on macrophage immunometabolism and atherosclerosis
在线阅读 下载PDF
导出
摘要 巨噬细胞在动脉粥样硬化斑块的起始、进展阶段直至斑块破裂中起核心作用,改变代谢途径是决定巨噬细胞功能和疾病进展的关键因素。本文阐述了动脉粥样硬化斑块微环境的核心因素如何影响巨噬细胞代谢变化以及代谢变化如何反过来改变巨噬细胞的免疫效应和组织修复功能,并探讨利用免疫代谢调节疾病中巨噬细胞反应的挑战和机遇。 Macrophages play central roles in the initiation,growth,and ultimately rupture of atherosclerotic plaques.Altered metabolism is the key feature that dictates macrophage function and subsequent disease progression.This review explores how the core factors of plaque microenvironment shape the metabolic rewiring of macrophages in atherosclerosis as well as how these metabolic shifts in turn alter the immune-effector and tissue-reparative functions of macrophage.Finally,this review offers insight into the challenges and opportunities of using immune metabolism to modulate macrophage responses in disease.
作者 陈羽斐 沈伟 施海明 CHEN Yufei;SHEN Wei;SHI Haiming(Department of Cardiology,Huashan Hospital,Fudan University,Shanghai 200040,China)
出处 《中国动脉硬化杂志》 CAS 2020年第1期74-80,共7页 Chinese Journal of Arteriosclerosis
基金 国家自然科学基金面上项目(81673701,81573710).
关键词 巨噬细胞 免疫代谢 动脉粥样硬化 macrophage immunometabolism atherosclerosis
作者简介 陈羽斐,硕士研究生,研究方向为冠心病与炎症反应,E-mail:13818401823@163.com;通信作者:沈伟,博士,副主任医师,研究方向为冠心病与血管新生,E-mail:drshenwei@aliyun.com。
  • 相关文献

参考文献3

二级参考文献24

  • 1王中群,李丽华,严金川,徐绥宁.糖基化终末产物与动脉粥样硬化的关系[J].中国动脉硬化杂志,2015,23(1):94-100. 被引量:16
  • 2王东,丁华,徐红岩,魏欣冰.洛伐他汀、普罗布考对小鼠巨噬细胞源性泡沫细胞内胆固醇含量的影响[J].中国药理学通报,2004,20(6):680-684. 被引量:17
  • 3孔炜,王宪.免疫炎症反应与动脉粥样硬化——高同型半胱氨酸血症促进动脉粥样硬化早期发病的免疫炎症机制[J].中国动脉硬化杂志,2007,15(7):525-526. 被引量:5
  • 4Li JJ, Kwak SJ, Jung DS, et al. Podocyte biology in diabetic nephropathy[J]. Kidney Int Suppl, 2007, 106:S36-S42.
  • 5Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy[J]. Clin Sci (Lond), 2013, 124: 139-152.
  • 6Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint[J]. Kidney Int, 2008, 74: 22-36.
  • 7Wang G, Lai FM, Lai KB, et al. Urinary messenger RNA expression of podocyte- associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker[J]. Eur J Endoerinol,2008, 158: 317-322.
  • 8Cheng J, Zhang W, Zhang X, et al. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis [J]. Clin J Am Soc Nephrol, 2012, 7: 391-400.
  • 9Deb DK, Sun T, Wong KE, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes[J]. Kidney Int, 2010, 77: 1000-1009.
  • 10He W, Kang YS, Dai C, et al. Blockade of Wnt/beta- catenin signaling by paricalcitol ameliorates proteinuria and kidney injury[J]. J Am Soc Nephrol, 2011, 22: 90-103.

共引文献56

同被引文献170

引证文献25

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部